Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... N.C. April 17, 2014 Meaningful long-term ... advanced cancer of the abdomen when treated with ... according to a first-of-its-size analysis by physicians at ... Baptist has the largest reported, single-center experience with ... A. Levine, M.D., and analysis of 20 years, ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... In India the only laboratory equipped to handle the avian ... Tiny vials of chicken blood and poultry tissue arrive each ... by the farmers from places that experience unusual chicken deaths ... Hare Krishna Pradhan, who heads the High Security Animal Disease ...
... always pleasurable to the eye and so are coloured veggies ... led by Dr. Isabelle Romieu of the National Institute of ... women consuming plenty of tomatoes, carrots and leafy greens appear ... per a report in the medical journal Thorax. Still, it's ...
... insomnia or loss of sleep affects finding way around negatively. ... is difficulty finding the way around.// ,This was tried ... rats' spatial memory was affected. ,Still, experts at UK ... the Journal of Neurophysiology. ,Two groups of rats were studied, ...
... Speculation that the Food and Drug Administration will give ... shares in ViroPharma to dip by about 33 percent. ... after Laura Alvey, a spokeswoman for the F.D.A said ... revised the bioequivalence recommendations for oral vancomycin from a ...
... are angry at the village heads, which has issued orders ... threatened to go on an indefinite strike unless the order ... directed district chief medical officers to take the attendance of ... the help of village chiefs or other local officials. ...
... is recovering well, after a cancer unit administered a potentially ... life, and is currently receiving specialist oxygen treatment. // She ... soon. ,Lisa Norris from Girvan in Ayrshire, ... overdose 17 times at the Beatson Oncology Centre in Glasgow. ...
Cached Medicine News:
... for capsulotomies, nucleus dislocating, and ... cystitomes are angled to conform ... lens, providing easier access to ... the potential for corneal touch. ...
23 gauge cannula (E4969 L) with 0.33 mm aspiration port, curved shaft and polished finish. Includes Teflon irrigating sleeve (E4969 SL). Uses 60 cm (23.6 inches) of silicone tubing (N5941 5). Overall...
... stools come with five legs for extra ... 25" (total vertical travel 6"). 2" ball ... and fire retardant upholstery, available in black ... special order. Features a contoured, padded, upholstered ...
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Medicine Products: